Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Munro

Showing results (331-340 of 335) with videos related to

Pageof 34
Sort By:
You have reached the last page of results.This site can display upto 335 results.
Lancet (London, England)|December 5, 2021
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trialAlasdair P S Munro, Leila Janani, Victoria Cornelius, et al.
The Journal of Infection|April 11, 2022
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trialXinxue Liu, Alasdair P S Munro, Shuo Feng, et al.
The Journal of Infection|April 21, 2023
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trialXinxue Liu, Alasdair P S Munro, Annie Wright, et al.
Lancet (London, England)|November 22, 2020
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trialMaheshi N Ramasamy, Angela M Minassian, Katie J Ewer, et al.
The New England Journal of Medicine|June 17, 2026
Cefazolin for Methicillin-Susceptible <i>Staphylococcus aureus</i> Bacteremia, Todd C Lee, Lauren A Barina, et al.
Pageof 34

Showing results (331-340 of 335) with videos related to

Sort By:
Pageof 34
You have reached the last page of results.This site can display upto 335 results.
Lancet (London, England)|December 5, 2021
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trialAlasdair P S Munro, Leila Janani, Victoria Cornelius, et al.
The Journal of Infection|April 11, 2022
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trialXinxue Liu, Alasdair P S Munro, Shuo Feng, et al.
The Journal of Infection|April 21, 2023
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trialXinxue Liu, Alasdair P S Munro, Annie Wright, et al.
Lancet (London, England)|November 22, 2020
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trialMaheshi N Ramasamy, Angela M Minassian, Katie J Ewer, et al.
The New England Journal of Medicine|June 17, 2026
Cefazolin for Methicillin-Susceptible <i>Staphylococcus aureus</i> Bacteremia, Todd C Lee, Lauren A Barina, et al.
Pageof 34